IQVIA Holdings stock gains support from analysts after earnings beat

Published on 09/18/2026 at 21:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IQVIA Holdings stock is backed by a Moderate Buy consensus as of September 18, 2026, with an average 12-month price target of USD 248. Recent quarterly results showed EPS of USD 3.15 on revenue of USD 4.37 billion, up 8.7 percent year over year.

Aquarell-Stadtpanorama mit modernen Bürogebäuden und Flussreflexionen bei Sonnenuntergang — IQVIA Holdings Firmensitz US46266C1053 als sanftes Aquarell mit Flussreflexion und warmem Abendhimmel über der Stadt, Illustration mit AI erstellt.

IQVIA Holdings stock (ISIN US46266C1053) is trading with solid analyst support after the company delivered better-than-expected quarterly figures, including earnings per share of USD 3.15 and revenue of USD 4.37 billion for its latest reported quarter, up 8.7 percent year over year, as of guidance and analyst data referenced on September 18, 2026.

Analysts back IQVIA with higher targets

According to MarketBeat on September 18, 2026, IQVIA Holdings Inc. (NYSE: IQV) carries a consensus rating of Moderate Buy from 17 research firms, with three hold ratings, 13 buy ratings and one strong-buy recommendation.

As MarketBeat reports, the average 12-month price target for IQVIA stock stands at USD 248.00, while several firms have recently raised their individual targets into a range between USD 276.00 and USD 288.00, signaling confidence in the company’s earnings trajectory.

In addition to the price targets, MarketBeat notes that IQVIA has set its fiscal year 2026 guidance for adjusted EPS in a range of USD 12.80 to USD 13.00, while sell-side analysts on average expect EPS of about USD 11.57 for the current year, giving investors a quantitative frame for future profit growth.

Earnings beat underpins the bull case

The latest reported quarterly figures play a central role in supporting the positive view on IQVIA Holdings stock. According to the analyst summary cited by MarketBeat, IQVIA reported adjusted earnings of USD 3.15 per share for its most recent quarter, beating the consensus estimate of USD 3.03 per share by USD 0.12.

On the top line, IQVIA generated revenue of USD 4.37 billion in the latest quarter, which exceeded analyst forecasts and represented an 8.7 percent increase compared with the same quarter a year earlier, according to MarketBeat.

For investors, this combination of an EPS beat and high-single-digit revenue growth is important because it shows that IQVIA is expanding both its scale and profitability, while still operating within the life-sciences services market that tends to be less cyclical than many other sectors.

Guidance and sector dynamics

The company’s forward-looking guidance adds another layer to the story. As highlighted by MarketBeat, IQVIA’s fiscal year 2026 adjusted EPS guidance of USD 12.80 to USD 13.00 implies a clear step up from the current-year EPS expectation of around USD 11.57, pointing to potential double-digit growth in earnings over the next reporting periods.

Beyond the company itself, IQVIA’s data also frame the broader deal environment in healthcare and biotech. In a separate discussion of merger-and-acquisition trends, Zacks cites IQVIA figures indicating that deal value in the sector reached roughly USD 130 billion in the first half of 2026, nearly matching the USD 133 billion recorded for all of 2025, underscoring a robust backdrop for IQVIA’s transaction-related services.

This elevated deal activity can be a tailwind for IQVIA because many of its offerings, from clinical research support to commercial analytics, are directly used by life-sciences firms that are active in mergers and acquisitions, making the sector environment a practical risk-and-opportunity factor for shareholders.

Stock price and trading range context

On the market side, IQVIA Holdings stock is trading within the upper half of its recent range. Per data on IQVIA’s listing on the New York Stock Exchange, the shares last closed at approximately USD 217.46 with an intraday trading range between USD 212.97 and USD 217.68, as of mid-September 2026.

The same price snapshot shows a 52-week range for IQVIA stock between USD 167.42 and USD 261.73, meaning that the latest price level around USD 217.46 sits comfortably above the 52-week low while still leaving upsideroom of more than USD 40.00 compared with the 52-week high, based on data as of September 18, 2026.

Market capitalization figures from equity research overviews indicate that IQVIA’s total equity value stands in the mid tens of billions of USD, positioning the company firmly within the large-cap segment of the health-care services space and making the stock a core holding for many institutional investors.

IQVIA stock closing level

IQVIA Holdings stock most recently closed at about USD 217.46 on the New York Stock Exchange as of September 18, 2026, trading within a 52-week band of USD 167.42 to USD 261.73 and reflecting the market’s ongoing assessment of its earnings power and guidance trajectory.